Active in the SBIR arena between1998-2003, CEL-SCI Corporation (formerly NYSEMKT:CVM: now AMEX:CVM) is again (2014-2020) SBIR funded by NIH in the space of vaccines for rheumatoid arthritis. Currrently engaged in immunotherapy R&D for treatment of cancer and other diseases, the firm's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. The firm's Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy.
